MeiraGTx (MGTX · NASDAQ)

HealthcareNASDAQUSASmall

MeiraGTx: Next-gen genetic medicines

A cutting-edge biotech with late stage genetic medicine programs. Backed by pharma giants, MeiraGTx is targeting blindness, Parkinson's and more.

MeiraGTx Holdings PLC

MGTX: NASDAQ

13.89 USD

+78.10%

year to date

Market Cap$1.33B

Avg Volume531.14K

Price$13.89-0.57%

P/E Ratio16.89ttm

Pricing delayed 20 minutes Sep 4, 2026, 8:00 PM

Strategic Partnership Powerhouse
Hologen AI and Oberland Capital deals provide capital and milestone upside while reducing risk
Gene-ius Manufacturing Moat
End-to-end capabilities generate revenue while reducing costs and risks
Regulatory Fast-Track Portfolio
RMAT designations and FDA alignment accelerate approval timelines significantly

Manufacturing Complexity
Gene therapy manufacturing remains technically challenging with potential for batch failures, regulatory delays, or capacity constraints.
Competitive Pressure
Well-funded rivals targeting similar indications limit market opportunity
Clinical Execution
High-stakes trials carry substantial failure risk despite positive interactions